US OptionsDetailed Quotes
SAGE250516P12500
- 7.60
- 0.000.00%
15min DelayClose Apr 24 16:00 ET
0.00High0.00Low
7.60Open7.60Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV37.10%PremiumMay 16, 2025Expiry Date4.71Intrinsic Value100Multiplier22DDays to Expiry2.89Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.89Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sage Therapeutics Stock Discussion
Sign in to post a comment
$Quoin Pharmaceuticals (QNRX.US)$ $Bridger Aerospace (BAER.US)$ $Mill City Ventures III (MCVT.US)$ $Elevation Oncology (ELEV.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $QMMM Holdings (QMMM.US)$ $Heramba Electric (PITA.US)$ $Black Diamond Therapeutics (BDTX.US)$ $Intra-Cellular Therapies(Delisted) (ITCI.US)$ $Traws Pharma (TRAW.US)$ $Sage Therapeutics (SAGE.US)$ $Glucotrack (GCTK.US)$ $Algorhythm (RIME.US)$ $Agape ATP (ATPC.US)$
📊⚡️📊
📊⚡️📊
4
1
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
74
30
10
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
Friday, 10th January at 6:49 pm
No Shareholder Action Required at This Time
Sage Therapeutics, Inc. (NASDAQ: SAGE) ("The Company"), today confirmed that Biogen Inc. (NASDAQ: BIIB) ("Biogen") has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share...
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
Friday, 10th January at 6:49 pm
No Shareholder Action Required at This Time
Sage Therapeutics, Inc. (NASDAQ: SAGE) ("The Company"), today confirmed that Biogen Inc. (NASDAQ: BIIB) ("Biogen") has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share...
8
3
$Sage Therapeutics (SAGE.US)$
Biogen Inc - Submits Non-Binding Proposal to Buy All Outstanding Shares of Sage Therapeutics' Common Stock Not Owned by Biogen for $7.22/Share in Cash
Biogen Inc - Submits Non-Binding Proposal to Buy All Outstanding Shares of Sage Therapeutics' Common Stock Not Owned by Biogen for $7.22/Share in Cash
$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...
$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...
$Sage Therapeutics (SAGE.US)$ Stock is good, but sentiment is negative. I don't see any significant and sustainable upside by Q3. Another 20% to 30% downside is 'Likely'
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...
3
$Sage Therapeutics (SAGE.US)$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint
4
$Sage Therapeutics (SAGE.US)$ what just happened
No comment yet
Newbee4 : $Bridger Aerospace (BAER.US)$